A primary care doctor I know used to spend the first ninety minutes of every evening finishing notes. Charts she couldn’t touch during the day because she was, you know, seeing patients. She calls it “pajama time.” Most clinicians have a name for it, and none of the names are affectionate.
That’s the problem ambient AI scribes are supposed to solve. They listen to the visit, draft the note, and hand it back for review — no typing, no dictation template, no scribe-in-a-box on a tripod. By 2026 this stopped being a pilot curiosity. There’s now a randomized controlled trial in NEJM AI, KLAS rankings that get cited in procurement meetings, and per-provider contracts that real health systems are signing at scale.
But “best AI medical scribe” is the wrong question. The right question is which one fits your EHR, your specialty, and your budget — because the gap between a $59/month solo tool and a $900/month enterprise platform isn’t mostly about note quality. It’s about integration depth and who’s on the hook when something goes wrong.
What actually separates these tools
Note quality has largely converged. The big vendors all produce a clean SOAP note from a normal visit. Where they diverge is everything around the note.
EHR integration depth. This is the whole ballgame for a health system. A scribe that drops a finished note directly into the right Epic encounter — coded, signed, ready — saves more time than a marginally better paragraph that you copy-paste out of a separate app. Some tools are Epic-native; some are a browser tab you babysit.
Specialty coverage. A 12-minute primary care visit and a 45-minute psychiatry intake are different animals. Tools trained heavily on ambulatory medicine can flail in behavioral health, surgery, or anything with dense procedural language.
Clinical evidence. Most vendor claims are marketing. The two signals that aren’t: KLAS scores (real customers rating real deployments) and peer-reviewed trials. In 2026 we finally have both worth citing.
HIPAA and the BAA. Table stakes, but check it anyway. You want a signed Business Associate Agreement, and you want to know whether audio is retained or discarded after the note is generated. “We’re HIPAA compliant” on a homepage is not a BAA.
Keep those four in mind and the field sorts itself out fast.
Abridge: the health-system default
If you walked into a large US health system in 2026 and asked what they’re using, the answer is probably Abridge. It’s deployed across 150+ health systems — Mayo Clinic, Johns Hopkins, UPMC, Kaiser — and it was rated best in KLAS for ambient documentation in both 2025 and 2026.
What earned that position is less the transcription and more the Epic integration. Abridge is built to live inside the Epic workflow rather than beside it, which is exactly what a CMIO cares about when rolling something out to four thousand clinicians. The note is structured, linked to the encounter, and traceable back to the conversation that produced it — so a physician reviewing a draft can click a claim and see where it came from. That traceability matters more than it sounds; clinicians don’t trust a note they can’t audit.
The catch is that Abridge is an enterprise product with enterprise pricing — figure roughly $300–$500 per provider per month, often inside a larger system contract, and not really sold to a solo doc with a laptop. If you’re a health system standardizing on Epic, it’s the safe default and the one your peers already validated. If you’re a two-person clinic, it’s not aimed at you.
Nuance DAX Copilot: deepest integration, deepest pockets
DAX Copilot is the Microsoft/Nuance offering, and it’s the most enterprise-grade option in the field — partly because Nuance has been doing clinical speech longer than anyone, and partly because Microsoft can wire it into the Office and Epic stack in ways smaller vendors can’t.
The differentiator a lot of buyers don’t weigh enough: DAX has a human quality-assurance option. For high-stakes specialties or risk-averse organizations, having trained reviewers in the loop on top of the model is a real safety feature, not a gimmick. It also integrates deeply with Epic and Meditech.
You pay for all of it. DAX is the priciest tool here — realistically $600–$900+ per provider per month once you fold in implementation, and it comes with annual contracts. There’s a wrinkle worth knowing: in the NEJM AI randomized trial (more on that below), DAX users showed no statistically significant reduction in time-in-note versus the control group over the study window. That doesn’t mean DAX is bad — adoption ramps, and the trial was a specific population over a few weeks — but it’s a useful reminder that the most expensive tool isn’t automatically the one that gives a given physician their evening back. Pilot it on your own clinicians before you assume the premium converts to time saved.
Suki: when you want an assistant, not just a stenographer
Suki’s pitch is different. Yes, it does ambient notes, but it also gives you voice control of the chart — you can place orders, pull up results, dictate into specific fields, and navigate the EHR by talking to it. It’s less “scribe” and more “voice assistant that happens to write your notes.”
For clinicians who want to drive the chart hands-free, that’s genuinely useful, and Suki integrates with the major EHRs (Epic, Cerner/Oracle, athenahealth, Meditech). It also lands at a friendlier price point than the enterprise heavyweights — Suki has been quoted as low as around $59/month on some plans, though realistic clinic deployments with integration run higher, into the low hundreds per provider.
The trade-off: voice control is only worth paying for if you’ll actually use it. Plenty of physicians just want the note written and don’t care to talk to their EHR. If that’s you, you’re paying for a capability you’ll ignore, and a pure documentation tool might serve you better for less hassle.
Nabla and DeepScribe: the evidence picks
These two are where the clinical-evidence story gets concrete, and they pull in opposite directions — one optimizes for measured efficiency, the other for accuracy and coding.
Nabla has the trial. The NEJM AI randomized study ran 238 outpatient physicians across 14 specialties, randomized to DAX Copilot, Nabla, or usual care, from late 2024 into early 2025. Nabla users saw a 9.5% drop in time-in-note versus control — about 41 seconds per note, from 4:30 down to 3:49. That sounds small until you multiply it by twenty notes a day, five days a week. Both tools showed signals of reduced burnout, though the study authors are appropriately cautious that those secondary findings need bigger trials to confirm. Nabla is also priced sanely for clinics — around $119 per user per month — which makes it one of the more defensible buys when finance asks for proof.
DeepScribe is the accuracy-and-coding play. It posts a 98.8/100 KLAS score and leans hard into E/M coding support, which is exactly what practices worried about revenue capture and documentation defensibility want to hear. If your pain is “my notes are fine but my coding leaves money on the table,” DeepScribe is built for that conversation. Pricing sits in the same $300–$500/provider/month band as the other mid-market tools.
Between them: pick Nabla if you want trial-backed efficiency at a clinic-friendly price, DeepScribe if accuracy and coding capture are the metrics your group lives or dies by.
The solo and small-clinic tier
Everything above assumes a budget and an IT department. Most clinicians have neither. For solo physicians and small practices, the calculus flips — you want fast setup, transparent pricing, and a tool you can turn on this afternoon without a six-week implementation.
Freed is the obvious starting point here, mostly because it does something the enterprise vendors refuse to: publish its price. Around $99–$149/month, sign up with a credit card, start tonight. It’s wildly popular with independent clinicians for exactly that reason. PatientNotes, Tali AI, and Vero round out the sub-$120 tier with similar low-friction onboarding.
What you give up is integration depth. These tools generally hand you a finished note that you paste into your EHR, rather than writing into the chart natively. For a solo doc that’s a perfectly fine trade — you’re not coordinating four thousand clinicians, you just want pajama time back. For a health system it’d be a non-starter. Match the tool to the size of the problem.
So which one
There’s no universal winner, but the decision collapses quickly once you know your setting.
Solo physician or small clinic: start with Freed for transparent pricing and instant setup. If you want trial-backed efficiency and can stretch a little, Nabla at ~$119/month is the value pick. Don’t overbuy enterprise integration you have no way to use.
Multi-specialty clinic: this is where it gets interesting. If coding capture is your priority, DeepScribe. If you want voice control of the chart, Suki. If you want the cheapest credible efficiency story to show the partners, Nabla. Run a two-week pilot with two or three of them on the same clinicians and let the time-in-note numbers decide.
Enterprise health system on Epic: Abridge is the default for a reason — KLAS leader, Epic-native, already validated by your peer institutions. Consider DAX Copilot if you specifically want human QA in the loop and have the budget for it, but pilot it against your actual adoption curve rather than trusting the brand.
A pilot checklist that predicts whether a rollout sticks: measure time-in-note before and after on real clinicians (not a demo), check note accuracy on your three hardest visit types, confirm the BAA and audio-retention policy in writing, and verify the note lands in the right place in your EHR without copy-paste. If a vendor won’t let you measure those four things in a two-week trial, that tells you something.
The honest summary is that the model writing the note stopped being the differentiator a while ago. What you’re really buying is how deeply it plugs into your chart and who stands behind the output. Figure out which of those you actually need, and the price tag mostly explains itself.
Try this: pick the one visit type that generates the most after-hours charting in your practice, and pilot two scribes on just that. The tool that wins your worst-case visit is usually the one worth rolling out everywhere.